This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FSTX F-star Therapeutics (FSTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About F-star Therapeutics Stock (NASDAQ:FSTX) 30 days 90 days 365 days Advanced Chart Get F-star Therapeutics alerts:Sign Up Key Stats Today's Range$7.12▼$7.1250-Day Range$4.42▼$7.1252-Week Range$2.07▼$7.12VolumeN/AAverage Volume709,213 shsMarket Capitalization$156.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. Read More Receive FSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FSTX Stock News HeadlinesAstria Therapeutics price target raised to $28 from $26 at OppenheimerNovember 14, 2024 | markets.businessinsider.comLake Street Remains a Buy on Aquestive Therapeutics (AQST)October 25, 2024 | markets.businessinsider.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 12 at 2:00 AM | Brownstone Research (Ad)Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body InjectorSeptember 18, 2024 | markets.businessinsider.comBicara Therapeutics Rises 39% in Debut on NasdaqSeptember 15, 2024 | marketwatch.comAnalysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and SAGE Therapeutics (SAGE)July 25, 2024 | markets.businessinsider.comBuy Rating for Astria Therapeutics: Promising STAR-0215 Outpaces Competitors with Strategic Trials and Market PotentialMay 10, 2024 | markets.businessinsider.comAstria Therapeutics: Strong Buy Rating on Robust Finances and Promising Clinical TrialsMay 10, 2024 | markets.businessinsider.comSee More Headlines FSTX Stock Analysis - Frequently Asked Questions How were F-star Therapeutics' earnings last quarter? F-star Therapeutics, Inc. (NASDAQ:FSTX) released its earnings results on Wednesday, November, 10th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.06. The business had revenue of $0.75 million for the quarter, compared to the consensus estimate of $7.18 million. What other stocks do shareholders of F-star Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC). Company Calendar Last Earnings11/10/2021Today7/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FSTX CIK1566373 Webwww.f-star.com Phone441223497400Fax508-381-0347Employees84Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.28 million Net MarginsN/A Pretax Margin-213.97% Return on Equity-57.08% Return on Assets-42.40% Debt Debt-to-Equity Ratio0.15 Current Ratio3.38 Quick Ratio3.38 Sales & Book Value Annual Sales$21.17 million Price / Sales7.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book1.51Miscellaneous Outstanding Shares21,980,000Free Float21,279,000Market Cap$156.50 million OptionableNot Optionable Beta0.85 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:FSTX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding F-star Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share F-star Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
